19
Jul
Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body�s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body�s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Lung cancer is the leading cause of cancer deaths globally.
Nivolumab small cell lung cancer. Horn l, spigel dr, vokes ee, et al. Lung cancer is the leading cause of cancer deaths globally. It’s for people with sclc that has metastasized (spread to other parts of the body) and has continued to get worse after being treated with at least 2.
Survival rates vary depending on the stage and type of the cancer when diagnosed. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body�s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Is this guidance up to date?
The us food and drug administration had approved the immunotherapy drug opdivo (nivolumab) to treat people with small cell lung cancer (sclc). The future of nivolumab in the treatment of sclc needs to be clarified with further clinical trials, in which improved patient selection and a more specific setting and/or timepoint of the disease may be identified. Bristol myers squibb has decided to withdraw the small cell lung cancer indication for opdivo (nivolumab).
Patients with idiopathic interstitial pneumonia (iip) have a higher risk of pneumonitis and are generally excluded from clinical trials. The following pieces of evidence underscored the rationale for investigating nivolumab and nivolumab plus ipilimumab in sclc: Giving cisplatin/carboplatin and etoposide together with nivolumab may work better in treating patients with extensive stage small cell lung cancer.
This is the first immunotherapy drug approval for sclc. There is a simple discount patient access scheme for nivolumab.